{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T13:01:44Z","timestamp":1775221304903,"version":"3.50.1"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EJR"],"abstract":"<jats:p>Objective:\u00a0Lung nodules (LNs) impose diagnostic and therapeutic challenges in patients with rheuma- toid arthritis (RA) due to unpredictable outcomes. Potential induction of nodulosis with the use of con- ventional synthetic DMARDs (csDMARD) and lack of knowledge regarding the effect of biologic disease-modifying anti-rheumatic drugs (bDMARDs)\/tofacitinib on the LN raise concerns and have an impact on treatment decisions. This study aims to evaluate the possible effects of the bDMARDs\/tofa- citinib and csDMARDS on LNs observed in RA patients.\n\nMethods:\u00a0Electronic health records of RA patients who had LNs detected on computed tomography (CT) between January 2015 and December 2020 were evaluated retrospectively. Patients with follow- up CT images were included in the study. Baseline and follow-up images were meticulously examined for the number, size, attenuation, and cavity formation. Clinical, histopathologic, and laboratory find- ings were analyzed.\n\nResults:\u00a0Forty-two RA patients with LNs were studied, 21 were on bDMARDs\/tofacitinib (11 females, mean age: 59.7\u00a06\u00a08.4) and 21 were on csDMARDs (12 females, mean age: 71.4\u00a06\u00a08.3). The proportion of patients with progressed nodules during follow-up was comparable between groups (six patients in bDMARDs\/tofacitinib vs seven patients in csDMARDs). Progression of LNs was observed in six patients in the bDMARDs\/tofacitinib group: three in anti-TNFa, two in rituximab, and one in abatacept users and none in tofacitinib users.\n\nConclusion:\u00a0Our results suggest that the risk of progression in LNs in RA patients with use of bDMARDs\/tofacitinib might not impose a higher risk compared to csDMARDs. Moreover, bDMARDs\/ tofacitinib might result in regression in LNs.\n\nCite this article as:\u00a0Karadeniz H, Cindil E, Babaog \u0306 lu H, et al. Treatment with bio- logic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients.\u00a0Eur J Rheumatol.\u00a02022;9(2):75-81.\n<\/jats:p>","DOI":"10.5152\/eujrheum.2022.21067","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T10:09:54Z","timestamp":1644228594000},"page":"75-81","source":"Crossref","is-referenced-by-count":5,"title":["Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients"],"prefix":"10.5152","volume":"9","author":[{"given":"Hazan","family":"Karadeniz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Babao\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asl\u0131han","family":"Avano\u011flu G\u00fcler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reyhan","family":"Bilici Salman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Sat\u0131\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuh","family":"Ata\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berna","family":"G\u00f6ker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eeminur","family":"Haznedaro\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Akif","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdurrahman","family":"Tufan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emetullah","family":"Cindil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3111","published-online":{"date-parts":[[2022,2,7]]},"container-title":["European Journal of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/download\/516\/516","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:10:40Z","timestamp":1753773040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/view\/516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,26]]}},"URL":"https:\/\/doi.org\/10.5152\/eujrheum.2022.21067","relation":{},"ISSN":["2148-4279"],"issn-type":[{"value":"2148-4279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]}}}